Vaccination has saved more lives and prevented more serious diseases than any advance in recent medical history. Every year, 2 – 3 million lives are saved across the world because of immunisation.
Alzheimer’s disease is one of Europe’s largest public health crises, but we won’t rest until new treatments can halt it in its tracks.
We won't rest until antibacterial monoclonal antibodies can slow antibiotic resistance and fight bacterial infections.
We won't rest until CAR-T cell therapies could help patients avoid a lifetime of treatment
We won’t rest until cell therapy can replace a lifetime of continuous insulin therapy for patients with diabetes.
Gene therapies offer a potential life change for patients with haemophilia B, and we won’t rest until similar rare diseases can be relieved or even cured.
Combining cancer treatments increases their power, helping people live healthier lives; we won’t rest until NSCLC can be kept under control or even cured.
Microbiome therapies are designed to lower C.difficile recurrence, lowering the risk of reinfection by 85% and greatly improving patients’ quality of life.
CGRP inhibitors will offer a new opportunity for migraine sufferers, lowering the number and severity of migraine attacks. We won’t rest until migraine suffers can find relief.
Therapies for NASH have the potential to reduce the build up of fat in the liver, which could avoid up to 12,000 transplants in Europe each year.
The ABPI has developed a tool to help build research relationships between the pharmaceutical industry and UK academics. The Library of Initiatives for Novel Collaborations (ABPI LINC) – a research database – will provide easy access to identify new collaboration opportunities.